Articles related to FDA

Healthcare professionals are navigating a complex dialogue on COVID-19 vaccine shedding, underscored by FDA acknowledgments and Pfizer protocols that hint at the nuanced risks of gene therapy product exposure.

The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.

In the evolving landscape of surgical innovation, the da Vinci robotic system exemplifies both the potential and the challenges of integrating advanced technology into patient care, underscoring the critical need for rigorous training and safety protocols.

The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.

In the fast-evolving landscape of oncology treatment, a new study reveals oncologists’ unique stance on FDA approval processes, emphasizing the importance of timely access to potentially life-saving drugs despite conventional evidentiary standards.

The FDA’s recent update to Paxlovid’s EUA ensures a seamless transition to NDA-labeled nirmatrelvir+ritonavir for treating high-risk pediatric patients, reflecting a commitment to adaptability and patient care in the ongoing fight against COVID-19.